Topic: blood cancer


8. Imbruvica

AbbVie and Johnson & Johnson's Imbruvica has emerged as the top dog in rare blood cancers despite a rush of challengers piling in. But in its most profitable indication, chronic lymphocytic leukemia, that competition is about to get stiffer.
Revlimid bottle

3. Revlimid

Despite more than a decade on the market, Bristol Myers Squibb’s Revlimid—formerly a Celgene bestseller—has kept growing in recent years despite patent challenges and growing competition. Riding a big approval in 2019, those good times are due to continue this year.